| Literature DB >> 34162723 |
Ann M Carias1, Jeffrey R Schneider2, Patrick Madden1, Ramon Lorenzo-Redondo3, Mariluz Araínga4, Amarendra Pegu5, Gianguido C Cianci1, Danijela Maric1, Francois Villinger4, John R Mascola5, Ronald S Veazey6, Thomas J Hope7.
Abstract
i.v. injected Abs have demonstrated protection against simian HIV infection in rhesus macaques, paving the way for the Antibody Mediated Prevention trial in which at-risk individuals for HIV received an i.v. infusion of the HIV broadly neutralizing Ab VRC01. However, the time needed for these Abs to fully distribute and elicit protection at mucosal sites is still unknown. In this study, we interrogate how long it takes for Abs to achieve peak anatomical levels at the vaginal surface following i.v. injection. Fluorescently labeled VRC01 and/or Gamunex-C were i.v. injected into 24 female rhesus macaques (Macaca mulatta) with vaginal tissues and plasma acquired up to 2 wk postinjection. We found that Ab delivery to the vaginal mucosa occurs in two phases. The first phase involves delivery to the submucosa, occurring within 24 h and persisting beyond 1 wk. The second phase is the delivery through the stratified squamous epithelium, needing ∼1 wk to saturate the stratum corneum. This study has important implications for the efficacy of immunoprophylaxis targeting pathogens at the mucosa.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34162723 PMCID: PMC8516693 DOI: 10.4049/jimmunol.2100253
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.426